Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Growth in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totalling 947,400 shares, an increase of 233.7% from the June 15th total of 283,900 shares. Based on an average daily volume of 4,250,000 shares, the short-interest ratio is currently 0.2 days.

Sonoma Pharmaceuticals Stock Performance

Shares of Sonoma Pharmaceuticals stock opened at $0.33 on Friday. The stock’s 50-day moving average is $0.21 and its 200-day moving average is $0.18. Sonoma Pharmaceuticals has a one year low of $0.12 and a one year high of $1.19.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its earnings results on Monday, June 17th. The company reported ($0.07) EPS for the quarter. The firm had revenue of $3.44 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 37.97% and a negative return on equity of 64.15%. Equities research analysts expect that Sonoma Pharmaceuticals will post -0.2 EPS for the current year.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.